{"id":1010816,"date":"2026-10-15T18:04:03","date_gmt":"2026-10-15T22:04:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/crescent-biopharma-announces-clinical-pipeline-momentum-including-enrolling-patients-in-standard-of-care-chemotherapy-combination-cohorts-of-global-phase-1-2-ascend-trial-of-cr-001-a-pd-1-x-vegf-bis\/"},"modified":"2026-10-15T18:04:03","modified_gmt":"2026-10-15T22:04:03","slug":"crescent-biopharma-announces-clinical-pipeline-momentum-including-enrolling-patients-in-standard-of-care-chemotherapy-combination-cohorts-of-global-phase-1-2-ascend-trial-of-cr-001-a-pd-1-x-vegf-bis","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/crescent-biopharma-announces-clinical-pipeline-momentum-including-enrolling-patients-in-standard-of-care-chemotherapy-combination-cohorts-of-global-phase-1-2-ascend-trial-of-cr-001-a-pd-1-x-vegf-bis\/","title":{"rendered":"Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1\/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001"},"content":{"rendered":"
\n

\n More than 125 patients dosed in ASCEND across the United States, Europe and South Korea; dose escalation complete<\/em>\n <\/p>\n

\n On track to report initial monotherapy data from ASCEND in Q1 2027, including antitumor response for a first-line non-small cell lung cancer (NSCLC) cohort<\/em>\n <\/p>\n

\n Enrolling patients in CR-001 plus standard of care chemotherapy combinations from ASCEND expansion cohorts in several solid tumor types in treatment-naive and previously treated patients, including first-line NSCLC, colorectal, biliary tract, gastric and endometrial cancers; on track to report initial data from hundreds of patients in mid-2027<\/em>\n <\/p>\n

\n Potential to start the first of multiple CR-001 Phase 3 studies in early 2028<\/em>\n <\/p>\n

\n Crescent and Kelun-Biotech rapidly advancing development of CR-001 as next generation immuno-oncology (IO) backbone: multiple sacituzumab tirumotecan (sac-TMT) + CR-001 Phase 2 studies ongoing in NSCLC and other solid tumors in more than 700 patients, with initial data expected in mid-2027; additional antibody-drug conjugate (ADC) combinations planned<\/em>\n <\/p>\n

\n Global Phase 1\/2 APOLLO trial of CR-002, a PD-L1-targeted ADC, on track to commence dosing this quarter; initial data expected in the second half 2027<\/em>\n <\/p>\n

\n Phase 1\/2 trial of CR-003 (SKB105), an ITGB6-targeted ADC, ongoing in China; initial data expected in Q1 2027<\/em>\n <\/p>\n

\n Anticipate more than 2,000 patients dosed across portfolio by mid-2027<\/em>\n <\/p>\n

WALTHAM, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) — Crescent Biopharma, Inc.<\/a> (\u201cCrescent\u201d or the \u201cCompany\u201d) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced clinical pipeline momentum, including enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care chemotherapy regimens in its global Phase 1\/2 ASCEND trial, as well as the initiation of additional antibody-drug conjugate (ADC) combination studies with CR-001.<\/p>\n

\u201cOur team\u2019s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000 patients to have been dosed across our portfolio. We remain focused on generating meaningful clinical data and expect to begin sharing results in the first quarter of 2027, including data from ASCEND, which is enrolling first-line NSCLC patients globally, including in the United States and Europe. We believe these data can support the initiation of the first of multiple Phase 3 studies of CR-001 in early 2028,\u201d said Joshua Brumm, chief executive officer of Crescent.<\/p>\n

\u201cOur partnership with Kelun-Biotech brings together two companies with a shared commitment to accelerating the development of potentially transformative therapies for people living with cancer. Multiple combination trials of CR-001 and sac-TMT are already underway in China, with additional ADC combination studies planned. In 2026, we established the foundation for the next phase of Crescent\u2019s growth: delivering multiple important clinical readouts across our IO and ADC portfolio, beginning early next year,\u201d said Mr. Brumm.<\/p>\n

\n Clinical Execution Progress in ASCEND, a Global Phase 1\/2 Trial of CR-001<\/strong>\n <\/p>\n

\n On track to report initial monotherapy data from ASCEND in Q1 2027<\/em>\n <\/p>\n